Balversa (erdafitinib) — United Healthcare
Non-small cell lung cancer
Initial criteria
- Diagnosis of non-small cell lung cancer
- Disease is metastatic
- Presence of FGFR genetic alterations
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Balversa therapy
Approval duration
12 months